Literature DB >> 6689657

Azathioprine and the liver. Evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans.

R A DePinho, C S Goldberg, J H Lefkowitch.   

Abstract

A patient with systemic lupus erythematosus developed jaundice and biochemical evidence of hepatic dysfunction 3 wk after initiation of azathioprine therapy. A liver biopsy specimen was obtained, and it showed canalicular cholestasis and centrilobular ballooning of hepatocytes. Clinical and serologic assessment excluded other causes of hepatic dysfunction, such as viral hepatitis, administration of other drugs, or worsening of the collagen disease and the patient was improved 2 wk after azathioprine was discontinued. This case adds further evidence that azathioprine is an idiopathic hepatotoxin with the potential for combined cholestatic and hepatocellular injury in humans.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6689657

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  11 in total

1.  Severe cholestasis due to azathioprine in Behcet's disease.

Authors:  Kadir Gisi; Murat Ispiroglu; Bulent Kantarceken; Hamide Sayar
Journal:  BMJ Case Rep       Date:  2019-03-31

2.  Cyclosporine A, FK-506, 40-0-[2-hydroxyethyl]rapamycin and mycophenolate mofetil inhibit proliferation of human intrahepatic biliary epithelial cells in vitro.

Authors:  Chao Liu; Thomas Schreiter; Andrea Frilling; Uta Dahmen; Christoph E Broelsch; Guido Gerken; Ulrich Treichel
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

3.  Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis.

Authors:  D E Lemley; L M DeLacy; L B Seeff; K G Ishak; D J Nashel
Journal:  Ann Rheum Dis       Date:  1989-04       Impact factor: 19.103

4.  Sclerosing hepatitis and azathioprine.

Authors:  J A Barrowman; P K Kutty; M U Ra; S N Huang
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

5.  Peliosis hepatis induced by 6-thioguanine administration.

Authors:  D Larrey; E Fréneaux; A Berson; G Babany; C Degott; D Valla; D Pessayre; J P Benhamou
Journal:  Gut       Date:  1988-09       Impact factor: 23.059

Review 6.  Current concepts in the diagnosis and management of autoimmune hepatitis.

Authors:  Stephen Kriese; Michael A Heneghan
Journal:  Frontline Gastroenterol       Date:  2012-11-12

Review 7.  Drug-induced cholestasis.

Authors:  H J Zimmerman; J H Lewis
Journal:  Med Toxicol       Date:  1987 Mar-Apr

Review 8.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

Review 9.  Drug therapy in the management of type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

Review 10.  Types, causes, and therapies of hepatitis occurring in liver transplant recipients.

Authors:  S Fagiuoli; G Shah; H I Wright; D H Van Thiel
Journal:  Dig Dis Sci       Date:  1993-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.